ARTICLE | Company News

Biocompatibles, Celsion, Cortius B.V., Glycostem Therapeutics, ISA Pharmaceuticals, IQ Corp. B.V., Percuros B.V., Biomedical Materials, Center for Translational

March 15, 2010 7:00 AM UTC

The Biomedical Materials program, the Center for Translational Molecular Medicine and Top Institute Pharma, all public-private partnerships, jointly awarded €28 million ($38.2 million) to seven research programs, including three projects for cancer, three for drug delivery and stem cells and an influenza program.

In cancer, IQ Therapeutics will work with Erasmus University, University Medical Center Groningen and the Max Planck Institute on the PC-mAbs project to develop patient-derived prostate cancer antibodies for imaging and therapy. Celsion, Philips, UMCU, Utrecht University, Technical University of Eindhoven, and the National Institute of Health will work on the HIFU-CHEM project to develop MRI-guided high intensity focused ultrasound (HIFU) to trigger release of temperature-sensitive targeted drugs to treat cancer. Percuros, ISA, Leiden University, Leiden University Medical Center and Utrecht University will develop a method for tracking therapeutic cancer vaccines after injection. ...